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The double inhibition of PDK1 
and STAT3-Y705 prevents liver 
metastasis in colorectal cancer
Wenjuan Qin1, Yun tian2, Jing Zhang3, Wenjian Liu4, Qiming Zhou5, Sheng Hu3, fei Yang6, 
Li Lu7, Haijie Lu1, Shuzhong cui2, Lu Wen8 & Shaozhong Wei7
As a key glycolysis enzyme, the significance of pyruvate dehydrogenase kinase 1 (PDK1) in the 
development of colorectal cancer (CRC) remains unknown. This study revealed that the prognosis of CRC 
patients with high levels of PDK1 was poor, and PDK1 knockdown significantly reduced liver metastasis 
of CRC in both nude mice and immune competent BALB/C mice. When combined with cryptotanshinone 
(CPT), an inhibitor of STAT3-p-Y705, the liver metastasis was further inhibited. PDK1 knockdown 
obviously increased reactive oxygen species level in anoikis conditions and subsequently resulted in 
an elevated anoikis, but the combination of PDK1 knockdown and CPT showed a reduced effect on 
anoikis. Based on this discrepancy, the adherence ability of CRC cells to matrix protein fibronectin was 
further detected. It showed that PDK1 knockdown significantly decreased the adherence of CRC cells 
to fibronectin when combined with CPT. These results suggest that inhibition of PDK1 can decrease the 
surviving CRC cells in blood circulation via up-regulation of anoikis, and inhibition of STAT3-p-Y705 can 
prevent it to settle down on the liver premetastatic niche, which ultimately reduces liver metastasis.
Colorectal cancer (CRC) is the third most common cancer in the world1. As the majority of the intestinal mes-
enteric drainage enters the portal venous system, the liver is the most common site of CRC metastasis2. Over 
50% of patients with CRC will develop liver metastasis, and more than two-thirds will ultimately die from this 
metastasis3. Hepatic resection of CRC metastasis in patients with isolated metastasis remains the only potential 
option for cure. Unfortunately, even with modern multi-modal anti-CRC therapy, 70% of patients still develop 
recurrence in the liver4.
Although cancer cells display a diverse range of metabolic profiles, the Warburg effect is a widespread trait5. 
It is noteworthy that mitochondrial function remains intact in most cancers. Pyruvate dehydrogenase kinase 
1 (PDK1) is the key glycolysis enzyme that leads to a switch in metabolism from mitochondria-based glucose 
oxidation to cytoplasm-based glycolysis. A series of studies showed that amplified expression of PDK1 was fre-
quently observed in solid tumors and hematological malignancies, such as ovarian cancer, head and neck cancer, 
glioma, melanoma, and acute myeloid leukemia6–10. Aberrant expression of PDK1 also correlated with unfavora-
ble outcomes in these malignancies. Additionally, PDK1 showed strong cytoplasmic activity in 70% of colorec-
tal tumors, compared with the complete (100%) absence of PDK1 expression in tumor-associated fibroblasts11. 
However, the prognostic value of PDK1 in CRC is still unknown.
Metabolism is intrinsically linked to cell death, as mitochondria plays a critical role in metabolism and apop-
tosis12. Anoikis, as a specific type of apoptosis, is induced by the loss of cell-matrix attachment13. Detachment 
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from the matrix stimulates the cells to generate reactive oxygen species (ROS), and excess ROS leads to cell death 
by stimulating the release of cytochrome c14. Thus, antioxidants protect detached cells from anoikis15. Moreover, 
the overexpression of PDKs antagonizes anoikis and prolongs cell survival in suspension in human mammary 
epithelial cells and melanoma cells16. Nevertheless, how PDK1 affects the growth and metastasis of CRC needs to 
be further clarified.
Results
The prognosis of CRC patients with high levels of PDK1 is poor, and knockdown of PDK1 
decreases the growth of CRC in vivo. The primary tumor tissue microarray involved a total of 100 
patients with CRC (staged I-IV). Most patients were over 60 years old, and the male-to-female ratio was 1:1.2. 
As expected, T2 and T3 stage, no lymph node metastasis and left-sided tumors correlated with increased overall 
survival, compared with T4 stage, lymph node metastasis and right-sided tumors (Fig. S1A–C). Additionally, 37 
patients and 42 patients were identified as high PDK1 expression and low PDK1 expression by immunohisto-
chemistry (IHC) respectively, except for unqualified staining on 21 patients. The clinical characteristics for these 
patients (n = 79) was summarized in Table S1. A Kaplan–Meier survival curve demonstrated that low PDK1 
expression was associated with increased overall survival, compared with high PDK1 expression (P = 0.0376, 
Fig. 1A). Figure 1B showed the representative expression of PDK1 in residual CRC.
Figure 1. High PDK1 expression is predictive of poor prognosis in CRC patients and promotes tumor growth 
in vivo. (A) Overall survival of CRC patients with high PDK1 expression (n = 42) was much shorter than 
patients with low PDK1 expression (n = 37). (B) IHC showed the representative results of low and high PDK1 
expression based on the staining index on a tissue microarray. (C) Nude mice were subcutaneously injected 
with 8 × 106 HCT116 cells with or without the transduction of PDK1 shRNA. Silencing PDK1 significantly 
slowed down the growth of HCT116 xenografts (P < 0.0001). (D) The gross xenografts were isolated from each 
nude mouse. (E) TUNEL assay showed that silencing PDK1 promoted the apoptosis of CRC cells in residual 
xenograft of nude mice. (F) Histogram displayed the corresponding comparison of the apoptosis cells per view 
presented in (E). Data expressed as mean ± S.D., **** represents P < 0.0001.
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Since increased PDK1 expression resulted in a poor prognosis in patients with CRC, we next investigated 
whether PDK1 contributed to the tumorigenesis in CRC in vivo. HCT116 cells transduced with PDK1 shRNA 
were subcutaneously injected into nude mice. Compared with the control, silencing PDK1 sharply suppressed the 
growth of HCT116 xenograft (Fig. 1C,D, P < 0.0001). A TUNEL assay was employed to examine the apoptotic 
cells in xenograft tissue. In line with the result of in vivo tumor growth, apoptotic HCT116 cells per field were 
significantly enhanced by silencing PDK1 (Fig. 1E,F, P < 0.0001). These data suggest that PDK1 plays a crucial 
role in the growth of CRC.
Knockdown of PDK1 decreases CRC cell proliferation and STAT3-Y705 phosphorylation. Next, 
we evaluated how PDK1 knockdown affected CRC cell viability and proliferation. CCK-8 assay demonstrated that 
silencing PDK1 resulted in a significantly higher cytotoxicity in HCT116 and SW480 cells (Fig. S2A). EdU assay 
was applied to examine whether blockage of PDK1 could inhibit the proliferation of CRC cells. As expected, flow 
cytometry indicated that blockage of PDK1 by shRNA decreased about 20% proliferation capacity of HCT116 
cells, compared with the scramble control (P < 0.0001, Fig. 2A,B). Similarly, silencing PDK1 reduced the prolifer-
ation capacity of SW480 cells by about 20% (Fig. S2B). Colony formation assay provided additional evidence for 
the key role of PDK1 in the tumorigenesis that HCT116 colony numbers were significantly reduced after PDK1 
was silenced (Fig. 2C,D, P < 0.0001).
It is generally accepted that STAT3 promotes tumorigenesis by regulating the expression of various target 
genes, including PDK117. To evaluate the role of endogenous PDK1 in STAT3 signaling, HCT116 cells with or 
without knockdown of PDK1 were treated with or without p-STAT3-Y705 inhibitor (cryptotanshinone, CPT). 
Western blots showed that silencing PDK1 obviously suppressed the levels of p-STAT3-Y705, compared with the 
control and the scrambled construct (Fig. 2E). In particular, the combination of PDK1 shRNA and CPT com-
pletely suppressed p-STAT3-Y705 (Figs 2E and S3). To test whether STAT3 interacts directly with PDK1 in CRC, 
a Co-IP assay was performed using an anti-PDK1 antibody in HCT116 and SW480 cells, which confirmed that a 
direct PDK1-STAT3 interaction indeed existed in these two CRC cells (Fig. 2F).
Silencing PDK1 and inhibiting p-STAT3-Y705 significantly reduces liver metastasis of CRC in 
both immune deficient and immune competent mice. It has remained unclear whether PDK1 is 
involved in the liver metastasis of CRC. For this purpose, we established a liver metastasis model in nude mice 
by performing intrasplenic injection of HCT116 cells without or with silencing PDK1. The results showed that 
the liver metastasis area was significantly reduced when PDK1 was silenced, compared with the non-transduced 
control (Fig. 3A, P < 0.01). Meanwhile, we further investigated whether inhibiting STAT3 phosphorylation could 
influence the efficacy of silencing PDK1 treatment. The results showed that the combined strategy of silenc-
ing PDK1 and CPT resulted in a sharply smaller area of liver metastasis, compared with silencing PDK1 alone. 
However, the combination of silencing PDK1 and total STAT3 inhibitor (SH-4-54) unexpectedly led to a worse 
efficacy than silencing PDK1 alone (Fig. 3B,C). To validate its efficacy in immune competent hosts, BALB/C mice 
were used to establish the liver metastasis model by the above same method. It showed a similar result with the 
immune deficient mice model (Fig. 4A,B), confirming that silencing PDK1 significantly inhibited liver metas-
tasis in CRC, and the simultaneous administration of CPT further improved its efficacy by down-regulation of 
p-STAT3-Y705 (P < 0.01), which was independent of host immune status. To strengthen the clinical translation, 
we further examined the efficacy of CPT with or without an unspecific PDK1 inhibitor (dichloroacetate, DCA), 
which also demonstrated that CPT or CPT plus DCA significantly reduced the liver metastasis of colon cancer, 
compared with the control group, moreover, the combined efficacy of CPT and DCA was better than that of single 
CPT treatment (Fig. S4).
The combinative effect of PDK1 knockdown and CPT on inhibiting liver metastasis was partly 
mediated by the sensitization to anoikis. Anoikis resistance is one of the major factors that contribute 
to cancer metastasis18. Some studies indicated that ROS regulated anoikis resistance either positively or negatively, 
depending on cell context19,20. To find out the potential reason why knockdown of PDK1 suppressed liver metas-
tasis in CRC, ROS levels of HCT116 cells were compared under different culture conditions. Firstly, HCT116 cells 
and HCT116 cells stably transduced with a negative vector, PDK1 shRNA-1 or shRNA-2, were seeded into 6-well 
plates. After 3 days of in vitro normal culture, the cellular ROS level was measured by flow cytometry. As shown 
in Fig. 5A, the ROS level did not show an obvious difference between the tested and control cells (both were about 
15%, P > 0.05). Secondly, a poly-HEMA culture was used to establish an anoikis model to measure ROS according 
to the above same method, which displayed that the ROS level of HCT116 cells with knockdown of PDK1 rose 
sharply to approximately 50%, which was significantly higher than that in controls (about 35%) (Fig. 5B,C). That 
is, ROS level of HCT116 cells was elevated when they were cultured in anoikis status, in particular, knockdown of 
PDK1 significantly correlated with a higher ROS level in anoikis status. Next, we examined the apoptotic rate of 
HCT116 cells in these two culture conditions. For normal culture, the apoptotic rate was about 10% at baseline, 
and it rose to approximately 18% after PDK1 was silenced (P < 0.01, Fig. 6A). As for anoikis culture, the base-
line apoptotic rate was similar with that in normal culture, however, the value was about 5 times higher when 
PDK1 was silenced (P < 0.0001, Fig. 6B,C). Moreover, silencing PDK1 significantly inhibited the expression of 
PDK1 and upregulated the expression of cleaved caspase-3 by western blot (Fig. S5A). We further examined the 
expression of antioxidative genes (SOD3, PRDX1) in HCT 116 cells with or without PDK1 knockdown in these 
two culture conditions. In normal culture, the expression of SOD3 and PRDX1 was downregulated when the 
PDK1 was silenced (Fig. S5B), but knockdown of PDK1 upregulated the expression of these two genes in anoikis 
condition (Fig. S5C), possibly resulting from a protective reaction against anoikis. These results indicated that 
knockdown of PDK1 promoted the apoptosis of HCT116 cells in anoikis condition by upregulation of cleaved 
caspase-3. Though PDK1 knockdown or CPT treatment upregulated the apoptosis of HCT116 cells in anoikis 
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condition, the combination of knockdown of PDK1 plus CPT significantly reduced the apoptotic rate of HCT116 
cells, compared with knockdown of PDK1 alone (Fig. 6D,E). Thus, additional mechanisms may be involved in the 
regulation of liver metastasis.
Knockdown of PDK1 plus CPT significantly reduces liver metastasis of CRC by downregulating 
the adherence capacity via inhibiting STAT3-p-Y705. Cancer cell invasion and adherence are the two 
leading causes for metastasis21, so we next further investigated the effect of inhibiting STAT3-p-Y705 on cell inva-
sion and adherence. Transwell experiment showed that the migration cells were less than 800 for silencing PDK1 
and/or CPT treatment, but the numbers were about 4000 for the two controls, suggesting that inhibiting PDK1 
and/or STAT3-Y705 phosphorylation significantly decreased invasion capacity of liver metastatic HCT116 cells 
(Fig. 7A,B, P < 0.0001). In addition, the average adherent cell numbers per view were less than 1500 for silencing 
PDK1 or the combination of CPT and silencing PDK1, however, the numbers were more than 3000 for the control 
Figure 2. The direct interaction between PDK1 and p-STAT3 may contribute to CRC proliferation. (A) EdU 
incorporation assay showed silencing PDK1 obviously decreased the proliferation of HCT116 cells in vitro, 
compared with the control. (B) Histogram displayed the corresponding comparison of the proliferation rate 
presented in (A). (C) Colony formation assay demonstrated that knockdown of PDK1 significantly decreased 
HCT116 cell colony formation in vitro. (D) Histogram illustrated the corresponding comparison of colony 
formation numbers presented in (C). (E) Western blot showed that knockdown of PDK1 significantly reduced 
STAT3-p-Y705 protein level in HCT116 cells. In particular, the Y705 phosphorylation was completely inhibited 
by the combination of CPT (a STAT3-p-Y705 inhibitor) and knockdown of PDK1. Three gels were loaded, and 
blots from different proteins were cropped and grouped into one image with white area separated in between 
different proteins. The exposure time was 50 s, 30 s, 10 s for p-STAT3, STAT3 and GAPDH, respectively. (F) A 
Co-IP showed PDK1 interacted directly with STAT3 in both HCT116 cells and SW480 cells. Rabbit IgG was 
served as the control. One gel was loaded, and the blot for STAT3 protein was cropped (exposure time: 40 s). 
Data expressed as mean ± S.D., **** represents P < 0.0001.
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without any treatment. In particular, the combination of these two treatments resulted in a significantly lower cell 
adherence capacity, compared with silencing PDK1 alone (P < 0.05, Fig. 7C,D), which means that the combined 
treatment significantly sensitizes liver metastatic HCT116 cells to a reduced adherence capacity and subsequently 
suppresses liver metastasis.
Figure 3. Knockdown of PDK1 and inhibiting p-STAT3-Y705 decreased liver metastasis of colon cancer in 
the nude mice model. (A) 5 × 106 HCT116 cells with or without PDK1 shRNA transduction were injected 
into the spleens of nude mice under isoflurane anesthesia on day 1, respectively. On day 9, the nude mice were 
sacrificed, and the liver metastatic area was measured by ImageJ software. Compared with the control group, 
knockdown of PDK1 significantly inhibited liver metastasis of HCT116 cells. (B) SH-4-54 (an inhibitor of 
total STAT3, 0.2 mg/d/mouse) or CPT (0.2 mg/d/mouse) were injected (i.p.) every other day (day 1, 3, 5, 7) 
for a total of four times. The results showed that CPT plus knockdown of PDK1 markedly decreased the liver 
metastasis area, compared with the combination of SH-4-54 and knockdown of PDK1. (C) Histogram indicated 
the corresponding comparison of liver metastasis areas presented in (A,B). Data expressed as mean ± S.D., * 
represents P < 0.05, ** represents P < 0.01.
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Discussion
Aerobic glycolysis in cancer cells is needed to supply glycolytic intermediates for anabolic support for cell prolif-
eration, but it remains unclear why pyruvate is preferentially disposed of as secreted lactate rather than utilized 
by the tricarboxylic acid (TCA) cycle. Cancer cells often increase their consumption of glutamine to replenish 
the TCA cycle22. Therefore, it appears that tumors aim to restrict the entry of pyruvate into the mitochondrial 
oxidative metabolism. Silencing PDK4 induced chemotherapy-associated damage in hepatocytes and colon can-
cer23, and decreased the cellular migration and invasion in colon cancer cells24, whereas up-regulation of PDK4 
increased the resistance of hepatocytes and colon cancer against chemotherapy induced toxicity23. These results 
suggest that PDK4 is involved in the development and drug resistance in CRC, though high hepatic, but not 
tumoural expression of PDK4 is associated with improved survival in patients undergoing surgical operation of 
resectable colorectal liver metastases23. In addition, the knockdown of PDKs in cancer cells stimulates glucose 
oxidation and ROS production, thus restoring the susceptibility of the cells to anoikis and reducing their ability to 
metastasize in normal cell line and melanoma16, which suggests that cancer cells may purposefully select aerobic 
glycolysis to reduce ROS production, avoid ROS mediated anoikis, and ultimately promote metastasis. Consistent 
with the study of Kamarajugadda et al.16, the present study showed that the knockdown of PDK1 sensitized CRC 
to anoikis by increasing ROS production.
Since acquiring anoikis resistance is the first step toward metastasis25, we next examined the significance of 
PDK1 in CRC metastasis. It demonstrated that silencing PDK1 in CRC cells significantly reduced liver metas-
tasis in both nude mice and immune competent mice. In particular, the addition of CPT further improved its 
efficacy. However, the combined treatment led to a lower anoikis than knockdown of PDK1 alone. This discrep-
ancy indicated that an additional mechanism contributed to the synergistic effect. Extracellular matrix (ECM), 
such as fibronectin, collagen, and laminins, was a major component of tumor microenvironment that played an 
essential role in tumor metastasis26–28. In addition, changes in the production and organization of fibronectin 
Figure 4. The combination of CPT and silencing PDK1 significantly inhibited liver metastasis of CRC by 
down-regulating p-STAT3-Y705 in the immune competent mice model. (A) 5 × 106 HCT116 cells with or 
without PDK1 shRNA transduction were injected into the spleens of BALB/C mice under isoflurane anesthesia, 
respectively. CPT (0.2 mg/d/mouse) were injected (i.p.) every other day (day 1, 3, 5, 7) for a total of four 
times. On day 9, the mice were sacrificed, and the liver metastatic area was measured by ImageJ software. The 
combination of CPT and PDK1 shRNA treatment led to a smallest liver metastasis area, compared with the 
control or PDK1 shRNA treatment alone. (B) Histogram indicated the corresponding comparison of liver 
metastasis areas presented in (A). Data expressed as mean ± S.D., **** represents P < 0.0001.
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in the ECM contributed to a favorable pre-metastatic niche29, which dictated the pattern of metastatic spread. 
Furthermore, Barbazán et al. reported that luminal side of liver blood vessels contained fibronectin deposits that 
were enriched in mice bearing CRC and human livers affected with metastases, more importantly, CRC cells 
attached to endothelial fibronectin deposits via talin1, a major component of focal adhesions, resulting in liver 
metastasis formation in vivo30. In this study, we further performed cell invasion and adherence assays, and found 
that CPT significantly decreased migration and adherence capacity of liver metastatic CRC cells by inhibiting 
STAT3-p-Y705, which is critical to prevent tumors from colonization in liver. This gives a reasonable explanation 
for the discrepancy that the combined treatment displays a lower anoikis, but results in a better efficacy. Thus, 
these results suggest that it may be a promising strategy to combine PDK1 and STAT3-p-Y705 inhibitor for effec-
tively reducing CRC metastasis.
The expression of PDK1 was considered to correlate with a variety of tumor progression markers and with 
patient prognosis. The inhibition of PDK1 with DCA has been investigated in several clinical trials, includ-
ing trials for glioma and refractory metastatic breast cancer (ClinicalTrials.gov Identifier: NCT01111097, 
NCT01386632, and NCT01029925)31. However, the high effective dosage and side effects have limited the appli-
cation of DCA32. To date, no clinical trial related to PDK1 inhibitors has been carried out for CRC. Therefore, it is 
necessary to explore new potent PDK1 inhibitors with a better safety profile and fewer side effects and to examine 
the activity of these inhibitors in CRC. Nevertheless, a major problem that must be taken into consideration for 
future application is that the inhibition of PDK1 can be only useful up to a certain point and may not be sufficient 
to cause extensive apoptosis in cancer cells alone33.
STAT3 is a key transcription factor for oncogenesis by upregulating several genes that control cell survival, 
angiogenesis, apoptosis, migration and cell cycle34. Demaria et al. demonstrated a non-canonical role of STAT3 
signaling involving the Warburg effect in a metabolomics analysis, in which the induction of aerobic glycolysis 
was an important component of STAT3 pro-oncogenic activities35. Moreover, STAT3 inactivation reversed the 
glycolytic shift by down-regulating key enzymes (including PDK) and then inhibited tumor growth36. Our find-
ings showed a direct interaction between PDK1 and STAT3 that silencing PDK1 significantly down-regulated 
p-STAT3-Y705 in CRC cells, suggesting a significant role of STAT3 signaling on cancer metabolism.
Figure 5. Silencing PDK1 significantly elevates the cytoplasmic ROS level. (A) HCT116 cells with or without 
the transduction of a PDK1 shRNA were cultured in normal condition. Flow cytometry showed ROS levels 
had no obvious difference regardless of PDK1 status. (B) As indicated in (A), cells were cultured in matrix 
detachment. ROS levels were significantly enhanced by silencing PDK1, compared with the controls. (C) 
Histogram indicated the corresponding comparison of ROS levels presented in normal and anoikis culture 
conditions in (A,B). Data expressed as mean ± S.D., **** represents P < 0.0001.
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Collectively, we suggest a model (Fig. 8) for the mechanism of inhibiting liver metastasis mediated by the 
combined treatment of CPT and knockdown of PDK1. Cancer cells will undergo anoikis when they break away 
from where they first form, and silencing PDK1 can reduce the numbers of cancer cells in the lymph system or 
bloodstream by elevated anoikis resulting from upregulation of ROS. Though some cancer cells inevitably spread 
to the liver, simultaneous inhibition of STAT3-p-Y705 significantly decreases the adherence of cell-matrix, and 
ultimately reduces the liver metastasis in CRC.
Materials and Methods
Cell culture and tissue microarray. The HCT116 and SW480 CRC cell lines were obtained from ATCC 
and maintained in high-glucose DMEM supplemented with 10% fetal calf serum (FCS, HyColony, Logan, UT). A 
tissue microarray involving the clinicopathological information of 100 patients with CRC cancer was purchased 
from Shanghai Outdo Biotech Company & National Engineering Center for Biochip Design and Engineering, 
China.
Figure 6. Anoikis partly contributes to the in vivo effect of the combination of knockdown of PDK1 and 
CPT. (A) HCT116 cells with or without the transduction of a PDK1 shRNA were seeded into 6-well plates and 
cultured in normal conditions. Then the cells were stained with AnnexinV-FITC/PI. Flow cytometry showed 
that the apoptosis rate was much higher after PDK1 was silenced. (B) As indicated in (A), the cells were seeded 
into 6-well plates coated with poly-HEMA. Flow cytometry showed that the apoptotic rate of HCT116 cells 
stably transduced with PDK1 was significantly higher than the other two controls. (C) Histogram indicated 
the corresponding comparison of the apoptosis rate presented in (A,B). (D) The results showed knockdown 
of PDK1 strongly sensitized CRC to anoikis; however, the anoikis rate was significantly reduced when PDK1 
silencing was combined with CPT. (E) Histogram indicated the corresponding comparison of the apoptosis 
results presented in both normal condition and suspending condition in (D). Data expressed as mean ± S.D., 
*** represents P < 0.001, and **** represents P < 0.0001.
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Figure 7. Knockdown of PDK1 plus CPT significantly reduces liver metastasis in CRC by downregulating the 
adherence capacity via inhibiting STAT3-p-Y705. (A) Transwell assay showed that the knockdown of PDK1 
or the combination of CPT and silencing PDK1 significantly decreased migration capacity of liver metastatic 
HCT116 cells. (B) Histogram indicated the corresponding comparison of migration capacity presented in (A). 
(C) The liver metastatic HCT116 cells were seeded into a 6-well plate coated with fibronectin. The adherence 
assay showed that the knockdown of PDK1 significantly decreased the chemotaxis of liver metastatic HCT116 
cells. In particular, the combination of CPT and knockdown of PDK1 resulted in a lowest cell adherence 
capacity. (D) Histogram indicated the corresponding comparison of the adherent cells presented in (C). Data 
expressed as mean ± S.D., * represents P < 0.05, ** represents P < 0.01, *** represents P < 0.001, and **** 
represents P < 0.0001.
Figure 8. The potential mechanism of knockdown of PDK1 and CPT on inhibiting liver metastasis in CRC.
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IHC staining. IHC was performed as described previously37. Briefly, tissue sections underwent deparaffini-
zation in xylene, followed by rehydration through graded ethanol at room temperature, which then were heated 
in a 1 mmol/L ethylenediaminetetraacetic acid (EDTA) buffer (water bath, 96–98 °C) for 15 min for antigen 
retrieval. Peroxidase activity was quenched with 0.3% hydrogen peroxide. The primary anti-PDK1 antibody (cat#: 
10026-1-AP, Proteintech Group, Inc, Rosemont, IL, USA) was used at a dilution of 1:100. Next, the slide was incu-
bated with a biotin-labeled secondary antibody for 30 min and streptavidin-horseradish peroxidase for 30 min. 
Diaminobenzidine was used as the chromagen and slide was counterstained with hematoxylin. A staining index 
(values, 0–2) that was determined by multiplying the score for staining intensity with the score for positive area 
was employed to determine the PDK1 expression level in CRC tissues. Scores ≥9 indicated high expression, and 
scores <9 indicated low expression.
TUNEL assay. After deparaffinization with xylene and rehydration through graded alcohols, proteinase K 
were added to the sections for 30 min at room temperature. After washing 3 times, the TUNEL detection solution 
was prepared according to the manufacturer’s instructions (Beyotime, China). The solution was added to the 
sections for 60 min of incubation at 37 °C. Apoptosis was examined under a fluorescence microscope (Olympus, 
Japan).
Colony formation assay. Five hundred cells were seeded in each well of a 6-well plate and maintained in 
2 ml of DMEM. The medium was changed every 3 days. Colonies were fixed with 4% poly-paraformaldehyde and 
stained with 0.25% crystal violet on day 14, and the numbers of colonies were manually counted.
CCK-8 assay. Cell cytotoxicity was determined using CCK-8 kits. Cells were seeded in 96-well plates at a 
density of 2 × 103 cells. After 3-day culture, 10 μl CCK-8 reagent was added to each well and incubated at 37 °C for 
another 1 h. Optical density values were measured at 450 nm using the microplate reader.
Cell invasion. Cell invasion was determined using a Transwell cell culture chamber (Becton-Dickinson; NJ, 
USA). A total of 1 × 104 cells cultured in serum-free DMEM containing 0.1% BSA were added to the upper cham-
ber and incubated for 24 h in the presence of 20% FCS in the lower chamber. The cells that migrated to the reverse 
side of a filter with an 8 μm pore were fixed with 4% poly-paraformaldehyde and stained with crystal violet after 
24 h. The data represented an average of three independent experiments that were conducted in duplicate.
Cell proliferation, ROS level and apoptosis assay. For EdU incorporation assay, the procedure was 
carried out according to the manufacturer’s instructions with EdU detection kits (NanJing KeyGen Biotech Co., 
Ltd.). Briefly, HCT116 cells or SW480 cells (with or without transfection of PDK1 shRNA) were seeded in 6-well 
plates. After 24 h, 2 × EdU working solution (20 µM) was added to the 6-well plates for 2 h culture at 37 °C, then 
the medium was discarded, followed by the addition of 1 ml fixing solution for 15 min at room temperature. Next, 
the fixing solution was discarded, and cells were washed 3 times, followed by the addition of 1 ml 0.3% Triton 
X-100 for 15 min. Finally, cells were cultured with 500 µl Click Reaction Buffer for 30 min at dark.
For ROS assay, HCT116 cells with or without transfection of PDK1 shRNA were cultured at both normal 
condition and anoikis condition for 24 h in 6-well plates. In the anoikis model, 6-well plates were coated with 
poly-HEMA (Sigma-Aldrich, USA). Then, the complete medium was discarded, followed by the addition of 1 ml 
serum free medium containing 2′,7′-dichlorodihydrofluorescein diacetate (final concentration: 10 mmol/L). After 
20 min culture, cells were washed with serum free medium for 3 times. Next, cells were digested with trypsin, and 
centrifuged at 500 g, 5 min. The supernatant was discarded, followed by the addition of 200 µl serum free medium.
For apoptosis assay, HCT116 cells were cultured with or without CPT treatment (10 μM) at normal condition 
or anoikis condition for 24 h. Then, cells were digested by trypsin, and centrifuged at 500 g, 5 min, followed by 
re-suspension with 195 μl Annexin V-FITC binding buffer, and 5 μl Annexin V-FITC, 10 µl PI at dark for 20 min.
Cells in these assays were finally subjected to flow cytometry (Cytomics FC500 Flow Cytometer, 260 Beckman 
Coulter) and finally analyzed by FlowJoTM version 10 (Tree Star, Inc., Ashland, OR, USA).
Cell adhesion. First, 24-well plates were coated with human fibronectin (Yeasen, China). CRC cells that 
were stably transduced with a PDK1 shRNA were incubated with or without 10 µM CPT and were then washed 
and counted. Equal numbers of cells were seeded into each well of the fibronectin-coated 24-well plate. After 
30 min of incubation, the plate was washed, and the supernatant was discarded. The cells were fixed with 4% 
poly-paraformaldehyde and stained with crystal violet. The images were captured under a microscope and ana-
lyzed by ImageJ software.
Western blotting analyses. Cellular lysates were prepared by suspending 1 × 106 cells in 100 µl of RIPA 
lysis buffer (1 × PBS, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% SDS) that was supplemented with 10 mM 
β-glycerophosphate, 1 mM sodium orthovanadate, 10 mM NaF, and 1 mM phenylmethylsulfonyl fluoride. 
The cells were extracted on ice for 30 min. The proteins were electro-transferred to nitrocellulose membranes 
(Millipore Corp., Bedford, MA), and specific proteins were detected using chemiluminescence. Anti-PDK1 anti-
body (cat#: 10026-1-AP), anti-Akt antibody (cat#: 10176-2-AP), anti-p-Akt (S473) antibody (cat#: 66444-1-Ig), 
anti-SOD3 antibody (cat#: 14316-1-AP), anti- GAPDH antibody (cat#: 60004-1-Ig), anti-PRDX1 antibody (cat#: 
15816-1-AP) were purchased from Proteintech Group, Inc, Rosemont, IL, USA. Anti-STAT3 antibody (cat#: 
9139), anti-p-STAT3 (Y705) antibody (cat#: 9145), anti-cleaved caspase-3 antibody (cat#: 9664) were purchased 
from Cell Signaling Technology Inc., Danvers, MA, USA. All primary antibodies were diluted at 1:500.
Co-IP analysis. The cells were lysed using IP lysis buffer (150 mM NaCl, 25 mM Tris-HCl at pH 7.4, 1 mM 
EDTA, and 1% NP-40) for 30 min on ice. The supernatant was harvested by centrifuge at 14,000 × g for 10 min 
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at 4 °C. 20 µl of A/G sepharose beads and 2 µg of rabbit IgG control antibody was added to a clean EP tube con-
taining 2 mg protein. The sample was rotated for 1 h at 4 °C, followed by centrifuge at 1000 × g for 1 min at 4 °C 
to pellet the IgG bound-A/G sepharose beads. Then the bead pellet was discarded, and the supernatant was 
transferred to a fresh EP tube containing either 5 µg rabbit IgG control antibody (cat# SP034, Solarbio Life Science, 
Beijing, China) or 5 µg anti-PDK1 antibody at a dilution 1:40 (cat# 3820, Cell Signaling Technology Inc., Danvers, 
MA, USA) plus A/G sepharose beads (40 µl) or A/G sepharose beads only. The IP lysis buffer was added to the 
mixture until the final volume was 500 µl. Then the sample was rotated overnight at 4 °C. To collect the immu-
noprecipitated protein, the sample was centrifuged at 1000 g for 1 min at 4 °C to pellet the antibody-bound A/G 
sepharose beads, and the supernatant was aspirated. The beads were re-suspended in 1 ml of IP lysis buffer and 
centrifuged at 1000 g for 1 min at 4 °C, and the supernatant was discarded, and this procedure was repeated for 
3 times. Finally, the beads was resuspended in 6 × laemmli buffer, boiled for 5 min at 100 °C, which was used to 
perform the SDS-PAGE western blot to detect the STAT3 protein.
Lentiviral package. PDK1 shRNA plasmids were extracted with an endo-free max kit (Omega, USA). The 
shuttle plasmids were mixed with the L1, L2, and VSVG package plasmids, which were transferred to 293FT. Viral 
supernatant was collected after 48 h, filtered through a 0.45 µm filter, and centrifuged at 75,000 g for 90 min at 4 °C. 
Next, the supernatant was discarded, and the pellet (lentiviral particles) was resuspended with PBS buffer. The 
stable cell line was screened and selected with puromycin for 2 weeks.
Xenograft animal model. All nude mice and BALB/C mice were housed and cared for according to the 
guidelines established by the Animal Care Committee of Sun Yat-Sen University, and the experimental protocol 
was approved by Medical School of Sun Yat-Sen University. Female nude mice (4–5 weeks old) were housed in 
a specific pathogen-free barrier system, and female BALB/C mice (7–8 weeks old) were maintained in environ-
mentally controlled conditions. 8 × 106 HCT116 cells were subcutaneously injected into the right flank of nude 
mice, and liver metastasis models (nude mice and BALB/C mice) were constructed through spleen injection of 
HCT116 cells (5 × 106 or 2.5 × 106). SH-4-54 (an inhibitor of total STAT3, 0.2 mg/d/mouse) or CPT (2 mg/ml, 
0.2 mg/d/mouse) were injected (i.p.) every other day (day 1, 3, 5, 7) for a total of four times. 50 µl DCA (0.5 mol/L) 
was administered (i.p.) every day (day 1–8) for a total of eight times. The volume of subcutaneous tumors was 
measured for 2 weeks and calculated as Volume (mm3) = (π × Length × Width × High)/6. The liver metastatic 
area was calculated by ImageJ software.
Statistical analysis. The continuous variables were analyzed using Student’s t-test. The survival curves for 
patients were analyzed by the STATA 15.1, and the growth curve for the nude mice model was compared using 
two-way ANOVA. All statistical analyses were performed using SPSS 11.0 software, and P < 0.05 was considered 
to be statistically significant.
Data Availability
All data generated or analyzed during this study are included in this published article (and its Supplementary 
Information Files).
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